An injectable HIV prevention drug is showing remarkable promise in reducing cases worldwide, yet millions who could benefit remain out of reach due to funding cuts that have dramatically slashed global HIV prevention investment.

The drug, known as injectable PrEP, represents a significant advancement in HIV prevention strategy. However, experts warn that recent cuts to programs like USAID's HIV initiatives are creating a critical gap between medical innovation and real-world access. This shortfall means that vulnerable populations in resource-limited settings may never get the chance to benefit from this life-saving technology. Read the full story →

Today's takeaway: Great medical breakthroughs only matter if we ensure the funding and systems are in place to get them to the people who need them most.